However, it is consistent with other studies, so it warrants further study to better understand the biological mechanisms. Public health implications The researchers acknowledged study limitations, including the potential for confounding in observational studies and the fact that several cancer types in the analysis had low event rates, leading to wide confidence intervals and limiting statistical power
10.1089/ars.2017.7269 17 BreenD
Tirzepatide is both a GLP-1 receptor agonist and a gastric inhibitory polypeptide (GIP) receptor agonist
By working with both incretin pathways your body already uses, tirzepatide may support deeper appetite regulation, larger and more sustained weight loss, and better glycemic stability than GLP-1 therapy alone
1B) were observed at the levels of rarefaction where graphs levelled off and the greatest number of samples was retained (multiple unpaired t-tests, corrected for multiple comparisons using the HolmSidak method)
